An experimental cancer vaccine from Moderna based on the messenger RNA technology used in successful COVID vaccines has been shown to work against melanoma.
The study is the first randomized trial to show that combining mRNA vaccine technology with a drug that revs up the immune response would offer a better result for melanoma patients and potentially for other cancers.
The ongoing study involved 157 patients with stage III/IV melanoma whose tumors were surgically removed before being treated with either the drug/vaccine combo or Keytruda alone with the aim of delaying disease recurrence. The personalized vaccine works in concert with Merck's Keytruda, a so-called checkpoint inhibitor designed to disable a protein called programmed death 1, or PD-1, that helps tumors to evade the immune system.
Moderna's personalized vaccine can be made in about eight weeks, a time frame the company eventually hopes to halve, Burton said.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Merck, Moderna share positive progress of potential skin cancer vaccineA potential skin cancer vaccine being developed using the same technology behind COVID shots fared well in a small study, the drug companies said. FOX13
Leer más »
Merck, Moderna share positive progress of potential skin cancer vaccineA potential skin cancer vaccine being developed using the same technology behind COVID shots fared well in a small study, the drug companies said.
Leer más »
Merck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Leer más »
Merck, Moderna detail potential skin cancer vaccine progressMerck and Moderna said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had the tumors removed in surgery.
Leer más »
Moderna and Merck team-up to fight melanomaVaccine-maker Moderna has partnered with the biopharmaceutical company Merck to create an effective treatment for skin cancer
Leer más »
Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%A combination of Moderna Inc's melanoma vaccine and Merck & Co's immunotherapy Keytruda cut the risk of skin cancer's recurrence or death by 44% compared with Keytruda alone in a mid-stage trial.
Leer más »